Nicole Hadas Net Worth

The estimated Net Worth of Nicole R. Hadas is at least $3 Миллион dollars as of 13 May 2024. Ms. Hadas owns over 12,016 units of Akebia Therapeutics stock worth over $937,790 and over the last 11 years she sold AKBA stock worth over $644,489. In addition, she makes $1,415,040 as Senior Vice President, Chief Legal Officer и Corporate Secretary at Akebia Therapeutics.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Hadas AKBA stock SEC Form 4 insiders trading

Nicole has made over 24 trades of the Akebia Therapeutics stock since 2014, according to the Form 4 filled with the SEC. Most recently she sold 12,016 units of AKBA stock worth $15,140 on 13 May 2024.

The largest trade she's ever made was selling 63,186 units of Akebia Therapeutics stock on 24 May 2023 worth over $77,087. On average, Nicole trades about 4,931 units every 100 days since 2014. As of 13 May 2024 she still owns at least 651,243 units of Akebia Therapeutics stock.

You can see the complete history of Ms. Hadas stock trades at the bottom of the page.

Nicole Hadas biography

Nicole R. Hadas serves as Senior Vice President, Chief Legal Officer, Corporate Secretary of the Company. She joined Akebia in 2013 and is Senior Vice President, Chief Legal Officer and Secretary. Prior to joining Akebia, Ms. Hadas was Vice President and General Counsel at OvaScience, Inc. in 2013. Previously, Ms. Hadas served as Senior Vice President and General Counsel at Inspiration Biopharmaceuticals, Inc., a company that filed for protection under Chapter 11 of the U.S. Bankruptcy Code in October 2012 prior to the successful sale of its hemophilia assets to Cangene Corporation and Baxter International in early 2013 for a total aggregate consideration that could exceed $1 billion. From 2001 to 2011, Ms. Hadas worked at Genzyme Corporation, now Sanofi Genzyme, most recently as Senior Corporate Counsel. Prior to Genzyme, she was an associate at Foley Hoag representing biopharmaceutical companies and healthcare providers in a wide variety of matters. Ms. Hadas received a B.A. from the University of Michigan and a J.D. from Boston College Law School.

What is the salary of Nicole Hadas?

As the Senior Vice President, Chief Legal Officer и Corporate Secretary of Akebia Therapeutics, the total compensation of Nicole Hadas at Akebia Therapeutics is $1,415,040. There are 2 executives at Akebia Therapeutics getting paid more, with John Butler having the highest compensation of $4,316,960.

How old is Nicole Hadas?

Nicole Hadas is 47, she's been the Senior Vice President, Chief Legal Officer и Corporate Secretary of Akebia Therapeutics since 2013. There are 15 older and 3 younger executives at Akebia Therapeutics. The oldest executive at Akebia Therapeutics Inc. is Adrian Adams, 69, who is the Independent Chairman of the Board.

What's Nicole Hadas's mailing address?

Nicole's mailing address filed with the SEC is C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, CAMBRIDGE, MA, 02142.

Insiders trading at Akebia Therapeutics

Over the last 11 years, insiders at Akebia Therapeutics have traded over $3,056,393 worth of Akebia Therapeutics stock and bought 2,141,907 units worth $27,915,834 . The most active insiders traders include Holdings A/S Novo, Muneer A Satter и Mark J Enyedy. On average, Akebia Therapeutics executives and independent directors trade stock every 28 days with the average trade being worth of $43,534. The most recent stock trade was executed by Nicole R. Hadas on 13 May 2024, trading 12,016 units of AKBA stock currently worth $15,140.

What does Akebia Therapeutics do?

akebia therapeutics, inc. is a biopharmaceutical company headquartered in cambridge, massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor (hif) biology. akebia’s lead product candidate, vadadustat, is an investigational oral therapy in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. akebia’s global phase 3 program for vadadustat, which includes the pro2tect studies for non-dialysis patients with anemia associated with chronic kidney disease and the inno2vate studies for dialysis-dependent patients, is currently ongoing. for more information, please visit our website at www.akebia.com.

Complete history of Ms. Hadas stock trades at Akebia Therapeutics

Akebia Therapeutics executives and stock owners

Akebia Therapeutics executives and other stock owners filed with the SEC include:

• John Butler,
  President, Chief Executive Officer, Director
• Michel Dahan,
  Chief Operating Officer, Senior Vice President
• Nicole Hadas,
  Senior Vice President, Chief Legal Officer, Corporate Secretary
• Dell Faulkingham,
  Senior Vice President, Chief Commercial Officer
• John P. Butler MBA,
  CEO, Pres & Director
• Dr. Steven Keith Burke,
  Sr. VP of R&D and Chief Medical Officer
• Dell Faulkingham,
  Sr. VP & Chief Commercial Officer
• Michel Dahan,
  Sr. VP & COO
• Jason A. Amello,
  Exec. Officer
• Adrian Adams,
  Independent Chairman of the Board
• Michael Rogers,
  Independent Director
• Maxine Gowen,
  Independent Director
• Michael Heffernan,
  Independent Director
• Cynthia Smith,
  Independent Director
• Mark Enyedy,
  Independent Director
• Steven Gilman,
  Independent Director
• Kristen Sheppard,
  Vice President, Investor Relations
• Myles Wolf,
  Independent Director
• Steven Burke,
  Senior Vice President, Chief Medical Officer
• David Spellman,
  Chief Financial Officer, Senior Vice President, Treasurer
• Douglas Jermasek M.B.A.,
  VP of Marketing & Strategy
• Mercedes Carrasco,
  Director of Corp. Communications
• Nicole R. Hadas,
  Sr. VP, Chief Legal Officer & Sec.
• Violetta Cotreau,
  Sr. VP, Chief Accounting Officer & Principal Accounting Officer
• Scott A Canute,
  
• Duane Nash,
  Director
• Ronald C Jr Renaud,
  Director
• Muneer A Satter,
  Director
• Michael D. Clayman,
  Director
• Bradley Maroni,
  SVP & Chief Medical Officer
• Anupam Dalal,
  Director
• Michael S Wyzga,
  Director
• Rita Jain,
  SVP, Chief Medical Officer
• Karen L Tubridy,
  SVP, Chief Development Officer
• Leanne M Zumwalt,
  
• Ron Frieson,
  
• Jodie Pope Morrison,
  
• Robert Shalwitz,
  Chief Medical Officer
• Bioventures Ltd Novartis,
  10% owner
• Holdings A/S Novo,
  10% owner
• Violetta Cotreau,
  SVP, Chief Accounting Officer
• Jason Amello,
  SVP, CFO & Treasurer
• Ellen Snow,
  SVP, CFO and Treasurer
• Nicholas Grund,
  Chief Commercial Officer
• Richard C Malabre,
  Chief Accounting Officer
• Erik Ostrowski,
  SVP, CFO, CBO & Treasurer